Hologic, Inc.’s (HOLX) GYN Surgical performance is expected to be driven by a robust international business and sales of MyoSure and the related Fluent system. The Breast Health division is likely to have slowly moved beyond the difficult prior-year comparisons, helped by the robust demand for its offerings and visible gantry orders. In addition, the molecular business may have driven the Diagnostics division’s performance led by its growth drivers.We anticipate the company’s fiscal 2024 third-quarter finan ...